IDEXX Laboratories, Inc. cash flow to debt ratio of 109.36% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

IDEXX Laboratories, Inc.'s free cash flow has increased 31.99% from $798.08M last year to $1.05B, signaling increasing performance

IDEXX Laboratories, Inc.'s debt to equity ratio is 0.60, which means that the company's assets are healthy financed, signaling financial stability.

IDEXX Laboratories, Inc.'s debt has decreased relative to shareholder equity from 0.62 last year to 0.60 today, signaling strengthened financials

IDEXX Laboratories, Inc. has a net debt to EBITDA ratio of 0.61x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

IDEXX Laboratories, Inc.'s interest coverage ratio of 37.31 indicates that earnings with good margin can cover interest payments on company debt

IDEXX Laboratories, Inc.'s profit margin has increased (9.87%) in the last year from 22.78% to 25.03%, signaling increasing performance

IDEXX Laboratories, Inc.'s short-term assets of $1.34B exceed its short-term liabilities of $1.15B

IDEXX Laboratories, Inc.'s return on assets of 33.11% is higher than the 5.00% threshold, indicating efficient asset utilization

IDEXX Laboratories, Inc.'s return on equity of 71.96%, is higher than 15.00%, indicating good performance

IDEXX Laboratories, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

IDEXX Laboratories, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

IDEXX Laboratories, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

IDEXX Laboratories, Inc. has a free cash flow yield of 2.24%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

IDEXX Laboratories, Inc.'s yearly earnings has increased 19.33% since last year from $887.87M to $1.06B, signaling increasing performance

IDEXX Laboratories, Inc.'s yearly revenue has increased 10.42% since last year from $3.90B to $4.30B, signaling increasing performance

ROIC 41.33% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

IDEXX Laboratories, Inc.'s 3-year revenue CAGR of 8.52% is positive, indicating growing revenue over the past 3 years

IDEXX Laboratories, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

IDEXX Laboratories, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

IDEXX Laboratories, Inc. is overvalued relative to its fair value price of 223.56 based on Discounted Cash Flow model

IDEXX Laboratories, Inc. has an earnings yield of 2.39%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

IDEXX Laboratories, Inc. is overvalued relative to its fair value price of 117.87 based on EBITDA multiple model

IDEXX Laboratories, Inc. has an EV/EBITDA ratio of 32.60x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

IDEXX Laboratories, Inc. is overvalued relative to its fair value price of 304.32 based on Earnings Fair Value model

IDEXX Laboratories, Inc. has a PEG-ratio over 1 which is considered overvalued

IDEXX Laboratories, Inc. has a price-to-book ratio of 29.59x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

IDEXX Laboratories, Inc. has a price-to-sales ratio of 10.48x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue